AbCellera Biologics Inc. 8K

AbCellera will report top-line Phase 2 trial results for ABCL635 for menopausal vasomotor symptoms on August 10, 2026, accompanied by an investor call and webcast.

AbCellera Biologics Inc. announced that it will release top-line results from its Phase 2 clinical trial of ABCL635, a potential first-in-class non-hormonal antibody drug targeting NK3R for the treatment of moderate-to-severe vasomotor symptoms due to menopause, before the market opens on Monday, August 10, 2026, and will host a live investor conference call and webcast at 4:30 a.m. Pacific Time (7:30 a.m. Eastern Time) that same day to discuss the data, with access and replay available via its investor relations website.

Filing Facts

CIK

1703057

Ticker

ABCL

Form

8K

Source Type

fda

Accession

0001703057-26-000049

Alert Tier

7